These are top 10 stocks traded on the Robinhood UK platform in July
On Monday, Bank of America (BofA) analysts reported a positive trend in the growth of weekly GLP-1 total prescriptions (TRx) for March, exceeding the growth observed in February and the average of the fourth quarter of 2024. According to the latest data, the average year-over-year growth rate of GLP-1 TRx for March was 48%, a slight improvement from the 47% growth rate in February and notably higher than the 44% growth rate recorded in the fourth quarter of 2024.
The analysts highlighted that the growth in March continues to surpass the lower growth rates seen in the spring of 2024, which had dipped to the mid-teens. This sustained increase indicates that the supply of GLP-1 treatments is likely improving. For the week ending March 28, the growth of new prescriptions (NRx) for GLP-1s was 42% year-over-year, compared to 36% in the previous week and 35% in the two weeks before that.
Furthermore, monthly sales growth of GLP-1 treatments in February was 41% year-over-year, which, while robust, was less than the 47% year-over-year growth seen in January but higher than the 36% observed in December. The consistent elevation in GLP-1 prescription growth since early spring 2024 suggests that the supply constraints experienced previously may be resolving, allowing for increased treatment availability.
The BofA report provides an updated snapshot of the GLP-1 market’s performance, reflecting a steady demand for these treatments. The continued upward trend in prescription growth rates is a positive sign for the market, as it indicates a recovery from the lower growth rates experienced during the previous year.
In other recent news, DENTSPLY SIRONA (NASDAQ:XRAY) Inc. has secured a $435 million bridge loan from Goldman Sachs Bank USA to enhance its financial flexibility. The funds are intended to repay existing obligations and support general corporate purposes. Meanwhile, Moody’s Ratings has revised DENTSPLY SIRONA’s outlook to negative from stable, citing growth challenges and earnings uncertainty, although the company retains its Baa2 issuer rating. The revision reflects Moody’s expectation of continued difficulties in sales of high-dollar equipment like CAD/CAM and imaging products. Additionally, Mizuho (NYSE:MFG) Securities has lowered its price target for DENTSPLY SIRONA from $21 to $18, maintaining a Neutral rating due to concerns about the adoption rate of the new Primescan 2 intraoral scanner. The company has also appointed David Ferguson as Senior Vice President, Global Business Unit Leader, bringing extensive experience from the MedTech and healthcare sectors. Ferguson’s appointment is expected to bolster the company’s strategic and operational goals. Furthermore, Needham analysts have downgraded ZimVie, a company within the same industry, from Buy to Hold, indicating broader concerns about the dental market’s growth prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.